Source 1review2015Thyroid
Toolkit/thyrotropin suppression therapy using levothyroxine
thyrotropin suppression therapy using levothyroxine
Also known as: levothyroxine thyrotropin suppression therapy
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine.
Usefulness & Problems
Why this is useful
Levothyroxine-based thyrotropin suppression therapy is listed as one component of initial thyroid cancer management. The abstract treats it as part of a broader treatment program that also includes surgery and radioiodine-related decisions.; initial management of thyroid cancer
Source:
Levothyroxine-based thyrotropin suppression therapy is listed as one component of initial thyroid cancer management. The abstract treats it as part of a broader treatment program that also includes surgery and radioiodine-related decisions.
Source:
initial management of thyroid cancer
Problem solved
It addresses a therapeutic management need in patients with thyroid cancer.; provides a hormone-based management component in thyroid cancer care
Source:
It addresses a therapeutic management need in patients with thyroid cancer.
Source:
provides a hormone-based management component in thyroid cancer care
Problem links
provides a hormone-based management component in thyroid cancer care
LiteratureIt addresses a therapeutic management need in patients with thyroid cancer.
Source:
It addresses a therapeutic management need in patients with thyroid cancer.
Published Workflows
Objective: Guide evidence-based diagnosis and management of adult thyroid nodules and differentiated thyroid cancer across initial evaluation, treatment selection, and long-term follow-up.
Why it works: The abstract describes a staged management logic in which initial evaluation informs biopsy decisions, biopsy interpretation and molecular markers refine diagnosis, and later surveillance uses imaging and serum thyroglobulin to monitor recurrent disease.
ultrasound-based biopsy triagebiopsy result interpretationmolecular-marker-informed evaluationimaging and serum thyroglobulin surveillanceelectronic database searchingcitation review and selectioncritical appraisalevidence grading
Stages
- 1.Initial evaluation of thyroid nodules(functional_characterization)
The abstract identifies initial evaluation as the first recommendation area for thyroid nodules.
Selection: Initial clinical evaluation before biopsy decisions
- 2.Clinical and ultrasound criteria for fine-needle aspiration biopsy(decision_gate)
This stage narrows which nodules undergo biopsy.
Selection: Clinical and ultrasound criteria determine whether FNA biopsy is indicated
- 3.Interpretation of fine-needle aspiration biopsy results(secondary_characterization)
Biopsy interpretation is explicitly named as a recommendation area after FNA decision-making.
Selection: Biopsy results are interpreted to inform management
- 4.Use of molecular markers(secondary_characterization)
The abstract lists molecular markers after FNA result interpretation, implying an adjunctive refinement stage.
Selection: Molecular-marker information is incorporated into thyroid nodule management
- 5.Staging and risk assessment for thyroid cancer(functional_characterization)
The abstract explicitly includes staging and risk assessment in initial thyroid cancer management.
Selection: Risk assessment informs initial thyroid cancer management
- 6.Initial thyroid cancer management(confirmatory_validation)
The abstract groups these interventions as initial management recommendations.
Selection: Management options include surgery, radioiodine remnant ablation and therapy, and levothyroxine-based thyrotropin suppression therapy
- 7.Long-term surveillance for recurrent disease(confirmatory_validation)
The abstract explicitly identifies surveillance for recurrent disease as part of long-term management.
Selection: Surveillance uses imaging and serum thyroglobulin
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
No mechanism tags yet.
Target processes
recombinationselectionImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
The abstract supports that this therapy is used in the thyroid cancer treatment setting and in conjunction with other management decisions such as staging and surgery.; applies within thyroid cancer management rather than nodule diagnosis
The abstract does not indicate that it replaces surgery, radioiodine, or surveillance.; the abstract does not specify dosing, patient selection, or outcome tradeoffs
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The guideline covers initial thyroid cancer management topics including screening, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and levothyroxine-based thyrotropin suppression therapy.
The guideline covers long-term differentiated thyroid cancer management including surveillance for recurrent disease using imaging and serum thyroglobulin, thyroid hormone therapy, recurrent and metastatic disease management, and consideration of clinical trials and targeted therapy.
Approval Evidence
1 source1 linked approval claimfirst-pass slug thyrotropin-suppression-therapy-using-levothyroxine
Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine.
Source:
review scope summarysupports
The guideline covers initial thyroid cancer management topics including screening, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and levothyroxine-based thyrotropin suppression therapy.
Source:
Comparisons
Source-stated alternatives
Other management approaches named nearby are surgical management and radioiodine remnant ablation and therapy.
Source:
Other management approaches named nearby are surgical management and radioiodine remnant ablation and therapy.
Source-backed strengths
explicitly included in the guideline's initial management recommendations
Source:
explicitly included in the guideline's initial management recommendations
Compared with cell-free system
thyrotropin suppression therapy using levothyroxine and cell-free system address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Compared with CfRhPDE1
thyrotropin suppression therapy using levothyroxine and CfRhPDE1 address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Strengths here: looks easier to implement in practice.
Compared with luciferin-luciferase pair
thyrotropin suppression therapy using levothyroxine and luciferin-luciferase pair address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection
Strengths here: looks easier to implement in practice.
Ranked Citations
- 1.